Clinical Trial

Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

Name: Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML — clinical trial record (NCT06665412)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects. The main efficacy is checked by MMR rate by 12 months from IP treatment.

Trial Details

NCT Number	NCT06665412
Lead Sponsor	Il-Yang Pharm. Co., Ltd.
Conditions	Chronic Phase Ph+ Chronic Myeloid Leukemia
Enrollment	168 participants
Start Date	2024-10-24
Primary Completion	2026-09-30 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-10-30